PROCEPT BioRoboticsMEX:PRCT 54 Receivables Turnover is 0.92 as of Mar. 2026. GuruFocus rates MEX:PRCT with a GF Score™ of 54/100 and a GF Value™ of MXN1,536.19 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 76.35% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PROCEPT BioRobotics's Revenue for the
three
months ended in Mar. 2026 was MXN1,499 Mil. PROCEPT BioRobotics's average Accounts Receivable for the
three
months ended in Mar. 2026 was MXN1,621 Mil.
Hence, PROCEPT BioRobotics's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.92.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PROCEPT BioRobotics Receivables Turnover Related Terms
PROCEPT BioRobotics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRCT vs ALMR, AHCO, ENOV: Receivables Turnover Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (MEX:PRCT) has a Receivables Turnover of 0.92 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #620 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 76.4%.
Is PROCEPT BioRobotics' Receivables Turnover too high?
PROCEPT BioRobotics' current Receivables Turnover is 0.92. The Medical Devices & Instruments industry median Receivables Turnover is 5.57. PROCEPT BioRobotics' value of 0.92 is 83.5% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #620 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Receivables Turnover compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #620 out of 812 companies for Receivables Turnover. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Receivables Turnover is 5.57. PROCEPT BioRobotics' value of 0.92 is 83.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.57, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Receivables Turnover of 0.92 is 83.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Receivables Turnover is 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,536.19, compared to a current price of MXN358.45 — trading 76.7% below its estimated fair value. The current Receivables Turnover is 0.92 and 83.5% below the Medical Devices & Instruments industry median of 5.57. PROCEPT BioRobotics' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current Receivables Turnover is 0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of MXN358.45 is trading 76.7% below its estimated GF Value™ of MXN1,536.19.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for MEX:PRCT:
Receivables Turnover: 0.92
GF Value™: MXN1,536.19 vs. price of MXN358.45 (76.7% below fair value)
Industry Position: 83.5% below the Medical Devices & Instruments median (#620 of 812)
No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
54GF Score
Get the complete analysis for MEX:PRCT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRCT has been successfully added to your 
